Page last updated: 2024-11-04

aristolochic acid i

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

aristolochic acid I: phospholipase A inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
AristolochiagenusA plant genus of the family ARISTOLOCHIACEAE. Species of this genus have been used in traditional medicine but they contain aristolochic acid which is associated with nephropathy. These are sometimes called 'snakeroot' but that name is also used with a number of other plants such as POLYGALA; SANICULA; ASARUM; ARISTOLOCHIA; AGERATINA; and others.[MeSH]AristolochiaceaeA plant family of the order Aristolochiales subclass Magnoliidae class Magnoliopsida. They are mostly tropical woody vines and a few temperate-zone species. The flowers are 3-parted; some species lack petals while others are large and foul smelling.[MeSH]

Cross-References

ID SourceID
PubMed CID2236
CHEMBL ID93353
CHEBI ID2825
SCHEMBL ID166284
MeSH IDM0040292

Synonyms (139)

Synonym
MLS002695974
chebi:2825 ,
CHEMBL93353 ,
8-methoxy-3,4-methylendioxxy-10-nitro-1-phenanthrencarbonsaeure
phenanthro(3,4-d)-1,3-dioxole-5-carboxylic acid, 8-methoxy-6-nitro-
nsc 11926
brn 0345159
birthwort
einecs 206-238-3
8-methoxy-6-nitrophenanthol (3,4-d) 1,3-dioxole-5-carboxylic acid
aristolochic acid-i
8-methoxy-3,4-methylenedioxy-10-nitrophenanthrene-1-carboxylic acid
8-methoxy-6-nitrophenanthro(3,4-d)-1,3-dioxole-5-carboxylic acid
ccris 1544
aristolochiazaeure
aristolochine
nsc 50413
3,4-methylenedioxy-8-methoxy-10-nitro-1-phenanthrenecarboxylic acid
c17h11no7
nsc-50413
KBIO1_001488
DIVK1C_006544
NCIMECH_000812
SPECTRUM4_001952
SPECTRUM_001156
IDI1_033910
tardolyt
tr 1736
nsc-11926
mls002702976 ,
nsc11926 ,
aristolochin
phenanthro[3,3-dioxole-5-carboxylic acid, 8-methoxy-6-nitro-
BIO2_000640
BIO1_000418
BIO1_001396
BIO2_000160
BIO1_000907
tnp00273
NCGC00017334-01
BSPBIO_002848
BSPBIO_001440
8-methoxy-6-nitro-naphtho[2,1-g][1,3]benzodioxole-5-carboxylic acid
phenanthro[3,4-d]-1,3-dioxole-5-carbocylic acid, 8-methoxy-6-nitro-
aristolochic acid a
NSC50413 ,
313-67-7
C08469
aristolochic acid
aristolochic acid i
aristolochic acid i, powder
NCGC00095981-03
NCGC00095981-01
NCGC00095981-02
KBIOSS_001636
KBIO3_000320
KBIO2_001636
KBIOSS_000160
KBIO3_000319
KBIOGR_000160
KBIO2_005296
KBIO3_002068
NCI60_000460
KBIOGR_002387
KBIO2_002728
KBIO2_006772
KBIO2_004204
KBIO2_000160
SPECPLUS_000448
SPECTRUM2_000822
SPECTRUM3_001114
SPBIO_000743
SPECTRUM1502233
SPECTRUM5_000729
NCGC00095981-05
NCGC00095981-04
8-methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid
HMS1989H22
smr001562128
HMS1791H22
HMS1361H22
2-naphthyl pyrovalerone-d8 hydrochloride
bdbm50306855
8-methoxy-6-nitro-phenanthro[3,4-d][1,3]dioxole-5-carboxylic acid
8-methoxy-6-nitronaphtho[2,1-g][1,3]benzodioxole-5-carboxylic acid
S9193
CCG-36162
CCG-35796
NCGC00017334-02
NCGC00017334-04
NCGC00017334-05
NCGC00017334-03
NCGC00017334-06
NCGC00017334-07
aristolochic acid 1
94218wfp5t ,
unii-94218wfp5t
FT-0602867
AKOS015896751
aristolochic acid, plants containing [iarc]
aristolochic acid [who-dd]
aristolochic acid [iarc]
aristolochia a
aristolochic acid [mi]
tr-1736
SCHEMBL166284
AC-34489
Q-100394
aristolochic-acid-a
8-methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid #
phenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid, 8-methoxy-6-nitro-
BBFQZRXNYIEMAW-UHFFFAOYSA-N
HMS3402H22
DTXSID0040969 ,
mfcd00004996
sr-05000002369
SR-05000002369-2
SR-05000002369-3
aristolochia, european pharmacopoeia (ep) reference standard
aristolochic acid i, european pharmacopoeia (ep) reference standard
aris-tolochic acid
1246815-48-4
BS-16911
aristolochic acid a,(s)
Q21099362
goq ,
8-methoxy-6-nitro-naphtho[1,2-e][1,3]benzodioxole-5-carboxylic acid
CS-0009050
aristolochic acid i;tr 1736
mixture of aristolochic acid a and b
HY-N0510
XA167153
aristolochicacida
aristolochia
gtpl12438
aristolochic acid, plants containing (iarc)
8-methoxy-6-nitrophenanthro(3,4-d)(1,3)dioxole-5-carboxylic acid
dtxcid8020969
aristolochic acid (iarc)

Research Excerpts

Overview

Aristolochic acid I (AAI) is an environmental and foodborne toxin found in the Aristolochia and Asarum species of plants that are widespread all over the world. It is a phytocompound that is linked to the progressive renal disease and development of human urothelial carcinoma.

ExcerptReferenceRelevance
"Aristolochic acid I (AAI) is a well established nephrotoxin and human carcinogen. "( Skullcapflavone II, a novel NQO1 inhibitor, alleviates aristolochic acid I-induced liver and kidney injury in mice.
Chen, C; Chen, SZ; Chen, XF; Dong, YP; Fan, ZC; Feng, F; Gu, YQ; He, HS; Jiang, LX; Sun, ZR; Wang, HY; Wen, W; Zhang, Y, 2023
)
2.6
"Aristolochic Acid I (AAI) is an environmental and foodborne toxin found in the Aristolochia and Asarum species of plants that are widespread all over the world. "( Generation of a high-affinity DNA aptamer for on-site screening of toxic aristolochic acid I in herbal medicines and botanical products.
Chen, M; Ke, S; Li, J; Liu, X; Tian, J; Yu, BY; Yu, H, 2023
)
2.58
"Aristolochic acid I (AAI) is a well-known genotoxic kidney carcinogen. "( Defining in vivo dose-response curves for kidney DNA adduct formation of aristolochic acid I in rat, mouse and human by an in vitro and physiologically based kinetic modeling approach.
Abdullah, R; Louisse, J; Punt, A; Rietjens, IMCM; Spenkelink, B; Wesseling, S, 2020
)
2.23
"Aristolochic acid I (AAI) is a potent nephrotoxic and carcinogenic compound produced by plants of the Aristolochiaceae family and thoroughly investigated as a main culprit in the etiology of Balkan endemic nephropathy (BEN). "( Aristolochic acid I: an investigation into the role of food crops contamination, as a potential natural exposure pathway.
Drăghia, LP; Lukinich-Gruia, AT; Oprean, C; Păunescu, V; Pavlović, NM; Tatu, CA, 2021
)
3.51
"Aristolochic acid I (AAI) is a phytocompound that is linked to the progressive renal disease and development of human urothelial carcinoma. "( Aristolochic acid I interferes with the expression of BLCAP tumor suppressor gene in human cells.
Huang, YT; Liu, BH; Lu, CC; Wu, TS; Yu, FY, 2018
)
3.37
"Aristolochic acid I is a nephrotoxic compound widely existing in many kinds of traditional Chinese medicines, especially in Aristolochiaceae medicinal plants. "( Hybrid-type carbon microcoil-chitosan composite for selective extraction of aristolochic acid I from Aristolochiaceae medicinal plants.
Chang, C; Du, W; Fu, Q; Ge, Y; Guo, PQ; Liu, RL; Luo, ZM; Shu, H; Xu, XY, 2018
)
2.15
"Aristolochic acid I (AAI) is a potent carcinogen and was found to be toxic in animal and clinical studies."( Aristolochic Acid I induces ovarian toxicity by inhibition of akt phosphorylation.
Kwak, DH; Lee, HS; Lee, S; Moon, JS; Park, JH, 2014
)
2.57
"Aristolochic acid I (AAI) is a plant alkaloid causing aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies. "( A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches.
Arlt, VM; Bárta, F; Hodek, P; Levová, K; Martínek, V; Schmeiser, HH; Stiborová, M, 2015
)
2.14
"Aristolochic acid I (AAI) is a natural plant alkaloid causing aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies. "( Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo.
Arlt, VM; Bárta, F; Dračínská, H; Frei, E; Hudecová, A; Kopka, K; Levová, K; Moserová, M; Schmeiser, HH; Stiborová, M, 2016
)
2.1
"Aristolochic acid I (AAI) is a plant drug found in Aristolochia species that causes aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies. "( Active Site Mutations as a Suitable Tool Contributing to Explain a Mechanism of Aristolochic Acid I Nitroreduction by Cytochromes P450 1A1, 1A2 and 1B1.
Arlt, VM; Bárta, F; Frei, E; Martínek, V; Milichovský, J; Schmeiser, HH; Stiborová, M, 2016
)
2.1
"Aristolochic acid I (AA-I) is a strong nephrotoxin, carcinogen, and mutagen found in plants such as the Aristolochia species. "( Alpha-Actinin-4 is a Possible Target Protein for Aristolochic Acid I in Human Kidney Cells In Vitro.
Cai, SQ; Jia, Y; Li, XM; Li, XW; Shang, MY; Shoyama, Y; Tan, HR; Wang, D; Wang, X; Xu, F; Yang, L; Yang, XX, 2016
)
2.13
"Aristolochic acid I (AAI) is a phytotoxin that has been found in various herbal remedies and linked to the development of human carcinogenesis. "( Aristolochic acid I suppressed iNOS gene expression and NF-κB activation in stimulated macrophage cells.
Lin, TH; Liu, BH; Liu, MC; Lu, CC; Wu, TS; Yu, FY, 2011
)
3.25
"Aristolochic acid I (AAI) is a primary nephrotoxin and carcinogen that is found in some Chinese herbal medicines, and AAI is responsible for the progression of aristolochic acid nephropathy. "( Cysteinyl leukotrienes synthesis is involved in aristolochic acid I-induced apoptosis in renal proximal tubular epithelial cells.
Cheng, J; Dou, Y; Du, Y; Li, L; Lou, Y; Tan, Y; Yang, H; Zheng, X; Zhu, D, 2011
)
2.07
"Aristolochic acid I (AA-I), which is a known nephrotoxin, is found in a commonly used Chinese medicine, Xixin, that originates from nine Asarum species (Aristolochiaceae) found in China. "( Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/atmospheric pressure chemical ionization/tandem mass spectrometry.
Cai, SQ; Chiang, ST; Hsai, JL; Hsiao, SS; Jong, TT; Lee, MR; Wu, TS, 2003
)
2.14

Effects

Aristolochic acid I (AAI) has been linked to the development of nephropathy and urothelial carcinoma in humans. AAI itself has no influence on the number of rosettes but compensates the diminuation caused by prednisolone.

ExcerptReferenceRelevance
"Aristolochic acid I (AAI) has been widely found in herbal remedies and linked to the development of nephropathy and urothelial carcinoma in humans. "( Aristolochic acid I induced oxidative DNA damage associated with glutathione depletion and ERK1/2 activation in human cells.
Chen, TW; Liu, BH; Wu, TS; Yu, FY, 2011
)
3.25
"Aristolochic acid itself has no influence on the number of rosettes but compensates the diminuation caused by prednisolone."( [Antagonistic effects of glucocorticoids and aristolochic acid on the immunocyte adherence phenomenon (author's transl)].
Müller, HJ; Siering, H, 1981
)
0.98

Actions

ExcerptReferenceRelevance
"Aristolochic acid is the cause of aristolochic acid nephropathy (AAN) and Balkan endemic nephropathy (BEN) and their associated urothelial malignancies. "( The effect of aristolochic acid I on expression of NAD(P)H:quinone oxidoreductase in mice and rats--a comparative study.
Arlt, VM; Bárta, F; Frei, E; Levová, K; Schmeiser, HH; Stiborová, M, 2014
)
2.21

Toxicity

Aristolochic acid I (AAI) is a potent carcinogen and was found to be toxic in animal and clinical studies. It is the main toxic component of aristolochiaceae plants such as Aristolochia. The report describes an investigation of the pathological mechanism of acute renal failure caused by toxic tubular necrosis.

ExcerptReferenceRelevance
"The acute toxic effects of aristolochic acid (AA) were tested in rats and mice of both sexes."( Acute toxicity of aristolochic acid in rodents.
Mengs, U, 1987
)
0.61
" Documentation of traditional Chinese herbal literature should help to ensure the safe use of Chinese herbs."( Toxicity of the Chinese herb mu tong (Aristolochia manshuriensis). What history tells us.
Zhu, YP, 2002
)
0.31
"(1) To study the acute and chronic toxicity of stem of Aristolochia manshuriensis (AMA Guanmuton) which is a Chinese medicinal herb in order to provide basis for safe clinical use."( Studies on the toxicity of Aristolochia manshuriensis (Guanmuton).
Chan, K; Hu, SL; Mei, QX; Zhang, HQ, 2004
)
0.32
"The LD50 with a 95% average trustable probability (P=0."( Studies on the toxicity of Aristolochia manshuriensis (Guanmuton).
Chan, K; Hu, SL; Mei, QX; Zhang, HQ, 2004
)
0.32
" Altogether, the examples presented illustrate that natural does not equal safe and that in modern society adverse health effects, upon either acute or chronic exposure to phytochemicals, can occur as a result of use of plant- or herb-based foods, teas, or other extracts."( Molecular mechanisms of toxicity of important food-borne phytotoxins.
Alink, GM; Boersma, MG; Martena, MJ; Rietjens, IM; Spiegelenberg, W, 2005
)
0.33
"The acute toxic effects of Aristolochia manshuriensis (GMT) and the total aristolochic acids (TA) were compared in mice with aristolochic acid A (AA) as the dose standard."( [Nephrotoxicity of Aristolochia manshuriensis and aristolochic acids in mice].
Ding, XS; He, R; Hui, LQ; Li, CY; Li, L; Liang, AH; Liu, BY; Wang, JH; Wu, ZL; Xiao, YQ, 2005
)
0.33
" LD50 values, the blood levels of BUN, Cr and ALT were measured."( [Nephrotoxicity of Aristolochia manshuriensis and aristolochic acids in mice].
Ding, XS; He, R; Hui, LQ; Li, CY; Li, L; Liang, AH; Liu, BY; Wang, JH; Wu, ZL; Xiao, YQ, 2005
)
0.33
"4 g x kg(-1) which was equivalent to 40 mg x kg(-1) as calculated by the content of AA in GMT extract, and this value was comparable with LD50 obtained from TA given intragastrically in mice (equivalent to 33 mg x kg(-1) of AA for male and 37 mg x kg(-1) for female)."( [Nephrotoxicity of Aristolochia manshuriensis and aristolochic acids in mice].
Ding, XS; He, R; Hui, LQ; Li, CY; Li, L; Liang, AH; Liu, BY; Wang, JH; Wu, ZL; Xiao, YQ, 2005
)
0.33
" Aristolochic acids existed in GMT are the main toxic components to cause renal toxicity which is a crucial cause to result in death."( [Nephrotoxicity of Aristolochia manshuriensis and aristolochic acids in mice].
Ding, XS; He, R; Hui, LQ; Li, CY; Li, L; Liang, AH; Liu, BY; Wang, JH; Wu, ZL; Xiao, YQ, 2005
)
0.33
"The rats of Radix Aristolochice showed serious toxic responses of renal tubule atrophy and necrosis, meanwhile, the levels of BUN, Cr and NAG were increased obviously."( [Nephrotoxicity of Radix Aristolochice and it's substitution material Radix Inulae in rats].
Li, LD; Liu, YY; Qiao, HX; Wu, LM, 2007
)
0.34
"We compared the short-term toxicity of toxic components of aristolochic acid in rats."( Short-term toxicity of aristolochic acid, aristolochic acid-I and aristolochic acid-II in rats.
Hsieh, HS; Hwang, DF; Lee, YT; Yeh, YH, 2008
)
0.59
" These results indicate that hepatic P450s play an important role in metabolizing aristolochic acid I into less toxic metabolites and thus have a detoxification role in aristolochic acid I-induced kidney injury."( Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity.
Ge, M; Gu, J; Li, L; Li, Y; Liu, L; Luo, H; Qi, X; Ren, J; Wang, C; Wang, H; Wu, X; Xiao, Y; Xie, T; Xue, X; Zhang, Y, 2008
)
0.57
" Therefore, the safe use of Asarum is questionable."( Comparative study on the aristolochic acid I content of Herba Asarifor safe use.
Chan, CL; Chan, HY; Jiang, ZH; Law, KW; Leung, KS; Liang, ZT; Man, TO; Sin, J; Zhao, ZZ, 2008
)
0.65
" Regulatory safety assessment for HMPs relies on both the assessment of cases of adverse reactions and the review of published toxicity information."( Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment.
Cunningham, DG; Jordan, SA; Marles, RJ, 2010
)
0.36
"Aristolochic acid I (AAI) is the major toxic component of aristolochic acid that causes aristolochic acid nephropathy and Balkan endemic nephropathy."( Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity.
Chen, M; Gong, L; Li, Y; Luan, Y; Pan, G; Qi, X; Ren, J; Wu, Y; Xiao, Y; Xing, G; Xue, X; Yao, J, 2011
)
2.04
"This report describes an investigation of the pathological mechanism of acute renal failure caused by toxic tubular necrosis after treatment with aristolochic acid I (AAI) in Sprague-Dawley (SD) rats."( Possible role of mtDNA depletion and respiratory chain defects in aristolochic acid I-induced acute nephrotoxicity.
Bao, Q; Huang, X; Jiang, Z; Li, H; Sun, L; Wang, T; Zhang, L; Zhang, S, 2013
)
0.83
" Except Aucklandia Radix, cytotoxicity study also showed that AA-containing herbs were more toxic than their corresponding genuine herbs and substitute."( Molecular identification and cytotoxicity study of herbal medicinal materials that are confused by Aristolochia herbs.
Au, KY; But, PP; Cheng, L; Lam, H; Li, M; Shaw, PC, 2014
)
0.4
" This work was designed to compare the acute and subacute toxicity of AF and HAF in order to provide references for safe clinical use and to evaluate the possibility of reducing toxicity of AF by honey-processing."( Acute and subacute toxicity of the extract of Aristolochiae fructus and honey-fried Aristolochiae fructus in rodents.
Chen, HF; Chen, L; Huang, Q; Luo, XQ; Ren, G; Shi, M; Yang, B; Yang, GH; Yang, M; Yang, WL; Yuan, JB, 2014
)
0.4
" Aristolochic acid I (AAI) is a potent carcinogen and was found to be toxic in animal and clinical studies."( Aristolochic Acid I induces ovarian toxicity by inhibition of akt phosphorylation.
Kwak, DH; Lee, HS; Lee, S; Moon, JS; Park, JH, 2014
)
2.76
" The isolated toxic compounds were purified through RP-HPLC."( Toxicity of aristolochic acids isolated from Aristolochia indica Linn (Aristolochiaceae) against the malarial vector Anopheles stephensi Liston (Diptera: Culicidae).
Kirubakaran, SA; Pradeepa, V; Sathish-Narayanan, S; Senthil-Nathan, S; Thanigaivel, A, 2015
)
0.42
"To analyze the toxic effects of aristolochic acid (AA) on developed kidneys in zebrafish larvae, zebrafish at 3 days postfertilization were treated with various concentrations of AA for 24 h before the status of kidney injury was investigated from several points of view."( Evaluation of nephrotoxic effects of aristolochic acid on zebrafish (Danio rerio) larvae.
Han, LW; Hou, HR; Hsiao, CD; Liu, KC; Peng, WB; Sun, C; Sun, GJ; Wang, RC; Wang, X; Zhang, Y, 2016
)
0.43
" This integrated microphysiological system provides an ex vivo approach for investigating organ-organ interactions, whereby the metabolism of a drug or other xenobiotic by one tissue may influence its toxicity toward another, and represents an experimental approach for studying chemical toxicity related to environmental and other toxic exposures."( Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity.
Chang, SY; Chapron, A; Dickman, KG; Eaton, DL; Gao, C; Grollman, AP; Himmelfarb, J; Kelly, EJ; Mao, Q; Neumann, T; Rosenquist, TA; Shen, D; Sidorenko, VS; Wang, J; Weber, EJ; Yeung, CK, 2017
)
0.46
" In order to understand the toxicity of aristolochic acids and the carcinogenic risks, as well as guide clinical safe medication, the experts suggested that:①Complete the systematical evaluation of aristolochic acids carcinogenicity as soon as possible."( [Study and opinion on toxicity of aristolochic acid].
Gao, Y; Liang, AH; Xiao, XH; Zhang, BL; Zhu, XX, 2017
)
0.46
" Foreign resources included PubMed and Cochrane library, and domestic research resources was China Food and Drug Administration(CDFA) Adverse Drug Reaction Monitoring Center database."( [Current research situation of nephrotoxicity of Chinese herbal medicine].
Chen, W; Fang, SN; Feng, X; Gao, YX; Liu, JP, 2018
)
0.48
" Two major genetic factors that are discussed include genetic polymorphisms in plasma membrane transporters that catalyze uptake and accumulation or efflux and elimination of environmental chemicals, and genetic polymorphisms in bioactivation enzymes that generate toxic and reactive metabolites."( Environmental and Genetic Factors Influencing Kidney Toxicity.
Lash, LH, 2019
)
0.51
"As the main toxic component of aristolochic acid, aristolochic acid I (AAI) is primarily found in Aristolochiaceae plants such as Aristolochia, Aristolochia fangchi and Caulis aristolochiae manshuriensis."( Untargeted LC-MS-based metabonomics revealed that aristolochic acid I induces testicular toxicity by inhibiting amino acids metabolism, glucose metabolism, β-oxidation of fatty acids and the TCA cycle in male mice.
Chen, H; Cui, Y; Han, J; Li, H; Liang, A; Ren, J; Shen, G; Song, N; Xu, B, 2019
)
1.02
"Aristolochic acid I (AAI) was regarded as the major toxic component of aristolochic acid (AA)."( The Disturbance of Hepatic and Serous Lipids in Aristolochic Acid Ι Induced Rats for Hepatotoxicity Using Lipidomics Approach.
Bian, B; Si, N; Wang, H; Wei, X; Yang, J; Yang, Y; Zhao, H; Zhou, J; Zhou, Y, 2019
)
1.96
" However, AA-containing herbs are highly safe in combination with berberine (Ber)-containing herbs in traditional medicine, suggesting the possible neutralizing effect of Ber on the toxicity of AA."( Berberine-Based Heterogeneous Linear Supramolecules Neutralized the Acute Nephrotoxicity of Aristolochic Acid by the Self-Assembly Strategy.
Feng, Y; Guo, W; Huang, G; Huang, X; Lei, H; Li, T; Li, Y; Tian, X; Wang, P; Xu, A; Yuan, K; Zhao, L; Zhen, J, 2021
)
0.62
"Aristolochic acid I (AA I) is one of the most abundant and toxic aristolochic acids that is reported to cause Aristolochic acid nephropathy (AAN)."( Protective Effects of Mitochondrial Uncoupling Protein 2 against Aristolochic Acid I-Induced Toxicity in HK-2 Cells.
Anger, EE; Feng, C; Li, J; Su, C; Su, S; Yu, F; Zhang, X; Zhao, S, 2022
)
2.4
"AH has no obvious toxicity to mice and is relatively safe when it is used in the form of decoction."( Long-term oral administration of Asarum heterotropoides f. mandshuricum (Maxim.) Kitag. decoction and its aristolochic acid analogs do not cause renal toxicity in mice.
Han, J; Li, C; Liang, A; Liu, C; Liu, M; Liu, S; Meng, J; Pan, C; Qin, S; Tang, X; Tian, J; Wang, F; Wang, L; Wang, Y; Yi, Y; Zhang, Y; Zhao, Y, 2023
)
0.91
" While the toxicity of AA-I and AA-II is relatively clear, there are marked differences in the toxic effects of different types of aristolochic acid analogues (AAAs)."( Study on the difference and correlation between the contents and toxicity of aristolochic acid analogues in Aristolochia plants.
Han, J; Li, C; Liang, A; Liu, C; Liu, M; Liu, S; Meng, J; Pan, C; Qin, S; Tang, X; Tian, J; Wang, F; Wang, L; Xian, Z; Yi, Y; Zhang, Y; Zhao, Y, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"To study pharmacodynamic characteristics by oral administration aristolochic acid I (AA-I) in rats."( [Studies on pharmacodynamic characteristics of aristolochic acid I in rats].
Cai, SQ; Li, XM; Qu, L; Su, T; Zhang, CL, 2004
)
0.82
"To study the accumulated toxic action to bandicoot of aqueous extract of crude and processed Radix Aristolochice and the pharmacodynamic action of aqueous and alcoholic extract of crude and processed Radix Aristolochice."( [Pharmacodynamic and toxicologic comparative study of crude and processed radix aristolochice].
Jiang, X; Li, CY; Wang, JH; Wang, ZM; Xue, BY, 2007
)
0.34
" Pharmacodynamic action wasnt obvious difference in same dose of crude product and processed one."( [Pharmacodynamic and toxicologic comparative study of crude and processed radix aristolochice].
Jiang, X; Li, CY; Wang, JH; Wang, ZM; Xue, BY, 2007
)
0.34
"Acute toxicity and chronic accumulated toxicity are stepped down after giving processed Radix Aristolochice, but pharmacodynamic effect wasn t lower."( [Pharmacodynamic and toxicologic comparative study of crude and processed radix aristolochice].
Jiang, X; Li, CY; Wang, JH; Wang, ZM; Xue, BY, 2007
)
0.34
"0mg/kg) of aristolochic acid sodium (AANa) to 4 respective groups of rabbits (n=6 for each dose), linear relationships between the doses of AA I and AA II and the area under the plasma concentration curve (AUC) were found to exist (p<0."( Pharmacokinetics and nephrotoxicity of aristolochic acid in rabbits.
Chen, SM; Fan, MY; Ho, Y; Hsu, KY; Tseng, CC, 2007
)
0.61
" After a single intravenous dose of 5 mg kg(-1) AA in rats, the pharmacokinetic parameters were estimated."( [Study of pharmacokinetics of aristolochic acid I and II in rats].
Chen, XJ; Fang, F; Lu, Q; Wang, GJ, 2008
)
0.63
" The main pharmacokinetic parameters were estimated to be as follows: CL = (0."( [Study of pharmacokinetics of aristolochic acid I and II in rats].
Chen, XJ; Fang, F; Lu, Q; Wang, GJ, 2008
)
0.63
" The relative pharmacokinetic parameters were compared systematically."( Comparative studies on the multi-component pharmacokinetics of Aristolochiae Fructus and honey-fried Aristolochiae Fructus extracts after oral administration in rats.
Chen, Y; Huang, Q; Li, J; Liang, J; Liu, X; Ren, G; Tang, Y; Wang, CZ; Yan, Z; Yuan, CS; Yuan, J, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" Differences in bioavailability or hepatic metabolism of AAI, expression of CYP1A2, or efficiency of a competing nitroreduction pathway in vivo may explain the apparent differences between human and rodent sensitivity to AAI."( Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse.
Dickman, KG; Einolf, HJ; Grollman, AP; Rosenquist, TA; Smith, A; Wang, L, 2010
)
0.64
" The reduced nitric oxide (NO) bioavailability reported in AAN might contribute to renal function impairment and progression of the disease."( Restored nitric oxide bioavailability reduces the severity of acute-to-chronic transition in a mouse model of aristolochic acid nephropathy.
Botton, O; Caron, N; Colombaro, V; Declèves, AE; Habsch, I; Jadot, I; Martin, B; Nortier, J, 2017
)
0.46
"A dihydroquercetin derivative (DHQA) was prepared through aminomethylation to overcome the low water solubility and bioavailability of dihydroquercetin (DHQ)."( Synthesis, characterization, solubilization, cytotoxicity and antioxidant activity of aminomethylated dihydroquercetin.
Chen, Y; Cui, J; Dong, J; Li, J; Ouyang, J; Wang, F; Wang, J, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" Adduct levels per 10(9) nucleotides in the liver after oral dosing daily for 5 days with 1 mg/kg AA and BHA (1 g/kg) or corn oil (5 ml/kg) for 7 days were as follows: (a) BHA and AA given simultaneously; 235 +/- 71, (b) AA + corn oil; 63 +/- 39, (c) AA followed by BHA; 57 +/- 13, (d) AA followed by corn oil; 91 +/- 38, (e) BHA followed by AA; 90 +/- 12, (f) corn oil followed by AA; 83 +/- 24."( Effect of butylated hydroxyanisole on the level of DNA adduction by aristolochic acid in the rat forestomach and liver.
Garner, RC; Lord, PG; Orton, TC; Routledge, MN, 1990
)
0.51
" By comparing the time course of stimulation and dose-response relationships between PGF2 alpha and PLC activity, it appears that oxytocin may stimulate PGF2 alpha secretion by activating PLC."( Cellular mechanisms by which oxytocin stimulates uterine PGF2 alpha synthesis in bovine endometrium: roles of phospholipases C and A2.
Burns, PD; Graf, GA; Hayes, SH; Silvia, WJ, 1997
)
0.3
"1) Administration of large dosage of Aristolochia manshuriensis Kom induces acute renal failure in rats."( Long-term outcome of acute renal injury induced by Aristolochia manshuriensis Kom in rats.
Chen, HP; Li, LS; Liu, ZH; Qiu, Q; Yin, HL, 2000
)
0.31
" Moreover, hypothesizing a linear dose-response relationship, the risk of developing ESRD linearly increased with ST-AF doses."( Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose.
Martinez, MC; Nortier, J; Vanherweghem, JL; Vereerstraeten, P, 2002
)
0.31
"(1) At month 0, 1 and 3, the occurrence of renal tumor or tumor-like proliferation was not observed; (2) At month 6, the occurrence of renal tumor-like proliferation in all the three AM dosage groups (50 g/kg, 30 g/kg and 20 g/kg) was 100."( [Experimental study on oncogenicity of Aristolochia manshuriensis in rats].
Liu, ZH; Qiu, Q; Yin, HL, 2001
)
0.31
"Large dosage of AM is oncogenic."( [Experimental study on oncogenicity of Aristolochia manshuriensis in rats].
Liu, ZH; Qiu, Q; Yin, HL, 2001
)
0.31
" These results differ from previous reports in that tumours originating from both epithelial and mesenchymal tissues were found, which may be attributed to the duration of treatment and the dosage of the drug."( Tumour induction in rats following exposure to short-term high dose aristolochic acid I.
Cui, M; Li, H; Li, LS; Liu, ZH; Qiu, Q, 2005
)
0.56
" Pattern recognition analysis indicated that the renal proximal tubule lesion was the main damage induced by AA, and the renal toxicity induced by AA was a progressive course with the accumulation of dosage by monitoring the toxicological processes from onset, development and part-recovery."( NMR-based metabonomic study on the subacute toxicity of aristolochic acid in rats.
Li, X; Liao, P; Ni, J; Pei, F; Wu, H; Zhang, X, 2006
)
0.58
"AM and LDXG in experimental dosage can induce renal injury, inflammatory cell infiltration in renal tubulointerstitium and high levels of IL-1beta, IL-6 presumpt that the nephrotoxicity of AM and LDXG refered to the immune mechanism."( [Nephrotoxicity of Aristolochia manshriensis and Longdan Xiegan decoction].
Xie, M; Zhang, N, 2007
)
0.34
" The difference in metabolic profiles between the control and the dosed rats was well observed by the principal component analysis (PCA) of the MS data."( Aristolochic acid induced changes in the metabolic profile of rat urine.
Cai, Z; Chan, W, 2008
)
1.79
" The deoxyguanosine adduct (dG-AA), however, was detected only in the kidney of rats that were dosed at 30mg AA/kg body weight for three consecutive days."( Quantification of aristolochic acid-derived DNA adducts in rat kidney and liver by using liquid chromatography-electrospray ionization mass spectrometry.
Cai, Z; Chan, W; Chan, YW; Kwong, DW; Poon, WT; Schmitz, OJ; Wong, RN; Yue, H, 2008
)
0.35
" The ratios of the detected AAI amount in urine compared to the dosing amount of AAI were approximately constant."( Determination of aristolochic acid I in rat urine and plasma by high-performance liquid chromatography with fluorescence detection.
Cai, Z; Chan, W; Guo, L; Yue, H, 2009
)
0.69
" A statistically significant linear dose-response relationship was observed between the prescribed dose of Mu Tong or the estimated cumulative dose of aristolochic acid and the risk of urinary tract cancer (P < ."( Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.
Chen, PC; Chen, YY; Lai, MN; Wang, JD; Wang, SM, 2010
)
0.36
"In this study, high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry in conjunction with chemometric methods including principal components analysis was used to investigate metabolic profiling in plasma samples from rats dosed with aristolochic acid (AA)."( Liquid chromatography/mass spectrometry for investigating the biochemical effects induced by aristolochic acid in rats: the plasma metabolome.
Cai, Z; Chan, W; Li, J; Lin, S, 2010
)
0.58
" Among the differentially expressed genes found in the dose-response and time-course studies that were involved in these biological processes, two up-regulated (GADD45B, NAIP), and six down-regulated genes (TP53, PARP1, OGG1, ERCC1, ERCC2, and MGMT) were con-firmed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR)."( Aristolochic acid suppresses DNA repair and triggers oxidative DNA damage in human kidney proximal tubular cells.
Bau, DT; Chen, YY; Chiang, SY; Chung, JG; Ho, TY; Hsiang, CY; Kao, ST; Wu, HC; Wu, KY, 2010
)
0.36
" Toxic effects from chronic or cumulative dosing are difficult to detect in the traditional setting and recent reports have demonstrated the health problems from Aristolochia species."( Toxicological risks of Chinese herbs.
Shaw, D, 2010
)
0.36
" The symptoms were observed in rats that were dosed with AA at a dosage of 10 mg/kg/day for 1 month."( Proteomics investigation on aristolochic acid nephropathy: a case study on rat kidney tissues.
Cai, Z; Chan, YW; Guo, L; Liu, N; Mak, YF; Poon, WT; Wu, HZ, 2011
)
0.37
"9 g/kg/day) (with an identical dosage of AAI), and empty capsules respectively for 180 days."( Kinetics of aristolochic acid I after oral administration of Radix Aristolochiae or Guanxinsuhe preparation in canines.
Chen, Z; Du, Y; Lou, YJ; Yang, HY; Zheng, XH; Zhu, DY, 2011
)
0.75
" The chronic AAN patients took the lowest AA-I dose per day but with the longest period and the highest cumulative dosage and exhibited a very large range of eGFR changing rate (from -21."( Aristolochic acid nephropathy: variation in presentation and prognosis.
Cai, SQ; Li, XM; Meng, LQ; Su, T; Wang, HY; Wang, X; Yang, L; Zou, WZ, 2012
)
0.38
" The nephropathy was induced using intravenous injections of aristolochic acid at a dosage of 10 mg/kg per day for 5 days and was characterized biochemically and histologically."( Urinary d-lactate levels reflect renal function in aristolochic acid-induced nephropathy in mice.
Chen, SM; Huang, TC; Lee, JA; Li, YC, 2013
)
0.39
" The correlation of cancer incidence with age, gender, dosage of aristolochic acid (AA), the type of renal replacement therapies, and the polymorphisms of quinone oxidoreductase 1 (NQO1) C609T and cytochrome P450 1A1 (CYP1A1) A4889G was examined."( Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China.
Chen, C; Lin, F; Liu, Y; Sun, M; Xu, F; Zhang, J; Zheng, C, 2015
)
0.42
" Cancer incidence was significantly associated with the dosage of AA consumption (p=0."( Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China.
Chen, C; Lin, F; Liu, Y; Sun, M; Xu, F; Zhang, J; Zheng, C, 2015
)
0.42
"The cancer initiation in our patients seems significantly correlate with the dosage of AA consumption."( Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China.
Chen, C; Lin, F; Liu, Y; Sun, M; Xu, F; Zhang, J; Zheng, C, 2015
)
0.42
" Subsequently, concentration-response curves obtained from in vitro cytotoxicity models were translated to in vivo dose-response curves using PBK model-based reverse dosimetry."( Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I.
Abdullah, R; Alhusainy, W; Punt, A; Rietjens, IM; Woutersen, J, 2016
)
0.63
" C57BL/6 mice were treated with AAI via intraperitoneal injection for an accumulated AAI dosage of 45 mg/kg body weight (BW) (15 mg/kg BW per day for 3 days)."( Renal chymase-dependent pathway for angiotensin II formation mediated acute kidney injury in a mouse model of aristolochic acid I-induced acute nephropathy.
Chang, CC; Chang, HF; Chang, TH; Chuang, WH; Hsieh, WY; Lin, CS; Lu, LC; Yang, CW, 2019
)
0.73
" To more thoroughly investigate the dose-response relationships, benchmark dose (BMD) analyses were performed with PROAST software."( Pig-a gene mutation assay study design: critical assessment of 3- versus 28-day repeat-dose treatment schedules.
Dertinger, SD; Elhajouji, A; Hove, TT; Martus, H; O'Connell, O, 2020
)
0.56
" Subsequently, the in vitro concentration-response curves were converted to predicted in vivo dose-response curves in rat, mouse and human kidney using PBK models."( Defining in vivo dose-response curves for kidney DNA adduct formation of aristolochic acid I in rat, mouse and human by an in vitro and physiologically based kinetic modeling approach.
Abdullah, R; Louisse, J; Punt, A; Rietjens, IMCM; Spenkelink, B; Wesseling, S, 2020
)
0.79
" The locals used these plant parts to prepare infusion and decoction traditional dosage forms for oral use."( Ethno medical knowledge and traditional use of Aristolochia bracteolata Lam. for malaria among local communities in Jubek State of South Sudan: A cross-sectional survey.
Deng, AL; Mathew, LS; Ogwang, PE; Peter, EL; Tolo, CU; Weisheit, A, 2021
)
0.62
" However, no DNA adducts were detected in the kidney, liver, and forestomach of orally dosed mice at 40 mg/kg/day for 2 days, and bone marrow micronucleus assay also yielded negative results."( Aristolochic acid IVa forms DNA adducts in vitro but is non-genotoxic in vivo.
Cao, Y; Chen, R; Chen, Y; Luan, Y; Wan, J; Xi, J; Yang, Z; Zhang, X, 2021
)
2.06
"Inf-L-At extract led to glycemic reduction with no dose-response at 15, 30, and 60 min comparable to that of the antidiabetic drug glibenclamide and was accompanied by an increase in hepatic and muscle glycogen contents."( Anti-hyperglycemic potential and chemical constituents of Aristolochia triangularis Cham. leaves - A medicinal species native to Brazilian forests.
da Rosa Guterres, Z; da Silva Pinto, L; de Araújo, FHS; de Oliveira Gomes Neves, K; de Oliveira, KMP; Heredia-Vieira, SC; Lima Cardoso, CA; Machado, MB; Mantovani Ferreira, GA; Nogueira, CR; Oesterreich, SA; Piva, RC; Trichez, VDK; Velter, SQ; Vieira, MDC, 2023
)
0.91
" However, the same AA-IVa dosage exhibited almost no nephrotoxicity and does not trigger RIF."( Differences in p38-STAT3-S100A11 signaling after the administration of aristolochic acid I and IVa may account for the disparity in their nephrotoxicity.
Han, J; Li, C; Liang, A; Liu, C; Liu, S; Meng, J; Pan, C; Tang, X; Tian, J; Wang, D; Wang, F; Wang, L; Wang, Y; Xian, Z; Yi, Y; Zhang, Y; Zhao, Y, 2023
)
1.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
nephrotoxinA poison that interferes with the function of the kidneys.
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
toxinPoisonous substance produced by a biological organism such as a microbe, animal or plant.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
cyclic acetalAn acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring.
organic heterotetracyclic compound
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
aristolochic acidsOrganic heterotetracyclic compounds which are a group of nitro phenanthrene organic acids, naturally found in many kinds of plants, such as Aristolochia and Asarum, and widely cultivated in Asia.They are identified as a class 1 human carcinogen by the International Agency for Research on Cancer owing to their carcinogenicity and nephrotoxicity and can pose a significant hazard to food safety and human health.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency22.33420.140911.194039.8107AID2451
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency19.96550.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency14.83250.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency34.81060.011212.4002100.0000AID1030
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency11.58210.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency31.62283.548119.542744.6684AID743266
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency14.12540.425612.059128.1838AID504891
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency14.12540.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency14.12540.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency14.12540.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency14.72130.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency4.10950.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency10.00000.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency6.02520.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency10.00000.020010.786931.6228AID912
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency7.94330.025911.239831.6228AID602313
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency6.68771.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cyclin-dependent kinase 2Homo sapiens (human)IC50 (µMol)20.00000.00041.044410.0000AID457604
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID1745849Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1745847CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745846Firefly Luciferase Counterscreen for Inhibitors of ATXN expression
AID1745848Confirmatory qHTS for Inhibitors of ATXN expression
AID1745850Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID344455Antispasmodic activity in guinea pig ileum assessed as inhibition of acetylcholine-induced smooth muscle contraction2008Journal of natural products, Jul, Volume: 71, Issue:7
Chemical constituents of Aristolochia constricta: antispasmodic effects of its constituents in guinea-pig ileum and isolation of a diterpeno-lignan hybrid.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID457612Inhibition of CDK2 at 50 uM2010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Semi-synthetic aristolactams--inhibitors of CDK2 enzyme.
AID247402Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
CHMIS-C: a comprehensive herbal medicine information system for cancer.
AID578749Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
A novel alkaloid, aristopyridinone A and anti-inflammatory phenanthrenes isolated from Aristolochia manshuriensis.
AID578748Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
A novel alkaloid, aristopyridinone A and anti-inflammatory phenanthrenes isolated from Aristolochia manshuriensis.
AID678071Mutagenicity in Salmonella typhimurium TA1002012Journal of natural products, Jul-27, Volume: 75, Issue:7
Aristoxazole analogues. Conversion of 8-nitro-1-naphthoic acid to 2-methylnaphtho[1,2-d]oxazole-9-carboxylic acid: comments on the chemical mechanism of formation of DNA adducts by the aristolochic acids.
AID398939Toxicity in Sprague-Dawley rat at 40 mg/kg
AID344454Antispasmodic activity in guinea pig ileum assessed as inhibition of electrically-induced smooth muscle contraction2008Journal of natural products, Jul, Volume: 71, Issue:7
Chemical constituents of Aristolochia constricta: antispasmodic effects of its constituents in guinea-pig ileum and isolation of a diterpeno-lignan hybrid.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID457604Inhibition of CDK22010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Semi-synthetic aristolactams--inhibitors of CDK2 enzyme.
AID398946Antifertility effect in Sprague-Dawley rat assessed as number of pregnant animals at 10 mg/kg administered postcoitally for 1 to 10 days
AID398940Toxicity in golden syrian hamster at 25 mg/kg
AID398941Antifertility effect in Sprague-Dawley rat assessed as number of pregnant animals at 40 mg/kg, po administered postcoitally for 1 to 10 days
AID1506511Cytotoxicity in HEK293 cells assessed as reduction in cell survival incubated for 48 hrs by MTT assay2017MedChemComm, Feb-01, Volume: 8, Issue:2
Synthesis, characterization, solubilization, cytotoxicity and antioxidant activity of aminomethylated dihydroquercetin.
AID227700Anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID678072Drug conversion assessed as formation of oxazole derivatives in presence of Zn/HOAc2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Aristoxazole analogues. Conversion of 8-nitro-1-naphthoic acid to 2-methylnaphtho[1,2-d]oxazole-9-carboxylic acid: comments on the chemical mechanism of formation of DNA adducts by the aristolochic acids.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,064)

TimeframeStudies, This Drug (%)All Drugs %
pre-199057 (5.36)18.7374
1990's78 (7.33)18.2507
2000's327 (30.73)29.6817
2010's448 (42.11)24.3611
2020's154 (14.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.18%)5.53%
Reviews71 (6.53%)6.00%
Case Studies31 (2.85%)4.05%
Observational2 (0.18%)0.25%
Other982 (90.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]